Microsoft appoints Anant Maheshwari as India President
Microsoft has appointed Anant Maheshwari as its India President from September 2016. He will take over the operations of the company from Chairman Bhaskar Pramanik from January 2017 as Pramanik retires in March next year. Currently, Anant is the President at Honeywell India.
Anant "will be responsible for all of Microsoft's product, service, and support offerings across India and continuing the company's transformation into the leading productivity and platform company for the mobile-first, cloud-first era", Microsoft said in a statement.
“Microsoft’s mission—empowering people and organizations across the planet to do more—is deeply energizing, especially at India’s current growth inflection point. The ambition of a mobile-first, cloud-first world complements India’s growth themes of Smart Cities and Digital India. The global mission and the ambition of the company are fully aligned with India’s needs and priorities, and enable a wide range of creative growth opportunities. I am excited to join the company at this transformational point and support the growth objectives globally and in India,” Maheshwari said.
Jean-Philippe Courtois, EVP and president of Microsoft Global Sales, Marketing & Operations said in a statement: “I am delighted to announce that Anant is joining Microsoft India. As we continue to transform as an organization and to support our customers’ digital transformation, Anant’s leadership will be pivotal to our continued growth. Our mission at Microsoft – which we all care deeply about – is to enable every person and every organization on the planet to achieve more. I know that in India, Anant will help us to continue to deliver against this, in one of the most vibrant, diverse and exciting markets anywhere in the world.”
Prior to Honeywell India, Maheshwari was with McKinsey & Company for six years where he worked with clients across multiple industries including telecom, IT and ecommerce, private equity, engineering equipment, automotive, steel, and pharmaceuticals.